Navellier & Associates Inc. Acquires 142,206 Shares of Aurinia Pharmaceuticals Inc $AUPH

Navellier & Associates Inc. raised its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 123.7% in the second quarter, Holdings Channel.com reports. The firm owned 257,142 shares of the biotechnology company’s stock after buying an additional 142,206 shares during the period. Navellier & Associates Inc.’s holdings in Aurinia Pharmaceuticals were worth $4,364,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BOK Financial Private Wealth Inc. purchased a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter worth approximately $32,000. Global Retirement Partners LLC bought a new position in shares of Aurinia Pharmaceuticals in the second quarter valued at approximately $41,000. Quantbot Technologies LP purchased a new position in shares of Aurinia Pharmaceuticals during the second quarter valued at approximately $45,000. Allworth Financial LP purchased a new position in Aurinia Pharmaceuticals during the 2nd quarter worth $56,000. Finally, Frazier Financial Advisors LLC boosted its holdings in Aurinia Pharmaceuticals by 411.9% during the first quarter. Frazier Financial Advisors LLC now owns 3,471 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 2,793 shares during the last quarter. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Price Performance

NASDAQ AUPH opened at $16.29 on Friday. The company has a market cap of $2.17 billion, a PE ratio of 7.11 and a beta of 1.42. Aurinia Pharmaceuticals Inc has a 52 week low of $10.34 and a 52 week high of $19.25. The company has a quick ratio of 4.97, a current ratio of 5.42 and a debt-to-equity ratio of 0.07. The firm’s 50-day simple moving average is $15.98 and its two-hundred day simple moving average is $15.49.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.04. The firm had revenue of $58.57 million during the quarter, compared to analyst estimates of $80.45 million. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. Research analysts predict that Aurinia Pharmaceuticals Inc will post 0.79 earnings per share for the current year.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, CEO Kevin Tang purchased 206,005 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were bought at an average cost of $15.28 per share, for a total transaction of $3,147,756.40. Following the purchase, the chief executive officer owned 13,044,106 shares of the company’s stock, valued at $199,313,939.68. This represents a 1.60% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on AUPH shares. Royal Bank Of Canada boosted their target price on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research note on Friday, August 7th. Zacks Research downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. Bloom Burton raised Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 20th. Wall Street Zen lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Weiss Ratings raised Aurinia Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $17.67.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.